Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Neurodegeneration, and COPD Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IREB2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IREB2 Full-Length / RRM Domain Recombinant Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Theoretical MW. Iron-sulfur cluster reconstituted (Holo-form) available. |
View IREB2 Products |
| Gene Delivery | IREB2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. CMV/EF1a promoter options. HEK293 packaging. |
View IREB2 Products |
| Benchmark Ab | Anti-IREB2 Recombinant Antibody Sequence-verified positive control for WB, IP, and IHC. |
View IREB2 Products |
| Validator | IREB2 siRNA Set (3 unique sequences) For knockdown verification and specificity controls in cellular IRE-binding assays. |
View IREB2 Products |
| Related Target A | TFRC (Transferrin Receptor) Downstream target stabilized by IREB2, critical for cellular iron uptake and ADC targeting. |
View TFRC Products |
| Related Target B | FTH1 (Ferritin Heavy Chain) Ferritin subunit translationally repressed by IREB2; biomarker for iron storage and ferroptosis. |
View FTH1 Products |
| Related Target C | IREB1 (IRP1 / ACO1) Paralog IRE-binding protein with 57% homology; essential for selectivity counter-screening and compensatory mechanism studies. |
View IREB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Protein Instability | Strictly Sequence Verified, High Purity (>95%) recombinant protein optimized for stability in cell-free binding assays. |
| Homolog Cross-Reactivity (IRP1 vs IREB2/IRP2) | Ortholog and homolog panel proteins available, strictly verified by mass spectrometry to ensure sequence fidelity. |
| Lack of Positive Controls for HTS | High-fidelity Recombinant Antibodies included to benchmark biochemical screening. |
| Target Validation Ambiguity | Sequence-verified siRNA included for precise gene silencing and functional readouts. |
| Iron-Sulfur Cluster Instability | Apo- and Holo- forms available. Cysteine-to-Serine mutants (C437S/C503S) for cluster stability and negative controls. |
Live IREB2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IREB2 (Iron-Responsive Element-Binding Protein 2) therapeutics is transitioning from fundamental iron metabolism biology to targeted interventions in oncology, chronic obstructive pulmonary disease (COPD), and neurodegeneration. As a master regulator of intracellular iron, IREB2 is a prime target for inducing or preventing ferroptosis—a specialized form of cell death. With the rise of targeted protein degradation (PROTACs) and novel small molecule inhibitors, researchers are moving past the limitations of traditional monoclonal antibodies. The next wave of R&D is heavily focused on highly selective intracellular modulators that can disrupt RNA-protein interactions or trigger IREB2 degradation without causing systemic iron toxicity. First-generation modulators are entering preclinical validation, with a focus on paralog-selective inhibition and combination strategies with iron chelation or ferroptosis inducers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Early Stage Biotech / Academic Spinoffs | Neurodegeneration (Alzheimer's, Parkinson's), Solid Tumors | Selectivity Assay (Need High-purity IREB2 vs IRP1 proteins for EMSA/SPR) |
| PROTAC / Degrader | Preclinical Pharma / Platform Companies | Prostate / Breast Cancers, Refractory Cancers | Degradation Validation (Need Sequence Verified IREB2 and Lentivirus for cell lines) |
| siRNA / ASO | Respiratory-focused Biotechs / RNA Therapeutics Firms | COPD, Lung Cancer, Myelodysplastic Syndromes | Knockdown Verification (Need Specific siRNA Sets and Control Antigens) |
| Ferroptosis Modulator | Oncology Pipelines | Therapy-Resistant Solid Tumors | Pathway Assessment (Need downstream targets like FTH1, TFRC) |
Key Mutations and Variants
IREB2 mutations are associated with disease and can impact protein expression and function. Notable variants include:
- In NDCAMA (Neurodegeneration with Cerebellar Ataxia and Mental Retardation): Mutations may drastically decrease protein expression level (UniProt P48200 VAR_082271, VAR_082272).
- In dbSNP: rs2230940: A common variant (UniProt P48200 VAR_058410).
These mutations underscore the importance of using sequence-verified recombinant proteins for accurate assay development and drug screening.
Molecular Differentiation & Assay Strategy
For best-in-class IREB2 drug development, key differentiation factors include:
- Affinity & Mechanism: High-affinity small molecules that disrupt IREB2-IRE RNA binding via steric hindrance; PROTACs that recruit E3 ligase for ubiquitination.
- Safety & Selectivity: Absolute selectivity over the paralog IRP1 (ACO1) to avoid systemic iron toxicity. Cross-reactivity panels using purified IREB1 and IREB2 proteins are essential.
- Delivery: BBB penetration for neurological indications; inhaled delivery for COPD.
Recommended screening assays:
- EMSA / FP: For evaluating disruption of IREB2-IRE RNA interaction.
- SPR / BLI: For high-precision binding kinetics.
- In vitro ubiquitination and degradation assays: For PROTAC evaluation.
- Paralog selectivity counter-screening: Using IREB1 recombinant protein.
TarMart provides high-purity (>95%), sequence-verified IREB2 recombinant protein, lentivirus for stable cell lines, and validated siRNA sets to support these assays.
Related Targets for Cross-Sell
- View TFRC Products: Transferrin Receptor 1, a direct downstream target of IREB2, widely used as an ADC target and ferroptosis marker.
- View FTH1 Products: Ferritin Heavy Chain, an iron storage protein translationally repressed by IREB2, serving as a pharmacodynamic marker.
- View IREB1 Products: IRP1, the paralog of IREB2, essential for selectivity screening and compensatory mechanism studies.
- View SLC40A1 Products: Ferroportin, the sole cellular iron exporter, co-regulating iron homeostasis with IREB2.